Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. freshman Avg
|
New words:
abroad, adenoviral, AntibioticsTM, ASU, bandage, billion, blockage, burst, chemical, chronic, chronically, cord, crossed, crystalline, cured, dealer, Delaware, developmental, diabetic, disposition, distinct, division, easier, encrustation, flat, floating, flushing, foot, France, gel, half, harbor, Honk, impractical, irrigation, irritancy, IRS, Japanese, jointly, killer, lifetime, long, margin, microbiological, mitigation, mixture, mode, moistening, move, Moving, mupirocin, Muranishi, neurology, NOL, Obama, occurrence, Odenberg, ophthalmology, opposed, oxidative, parallel, partnership, passage, pathogen, perpetual, physiologically, pilot, population, predetermined, pressure, profile, programatic, propensity, quantitative, randomized, recoverability, redirection, reform, Reincorporation, serial, serving, slowly, spinal, stake, standpoint, superbug, superficial, susceptible, Switzerland, territory, top, transparency, UCBE, ulcer, Ullakko, unamortized, underserved, undiscounted, unlimited, urology, User, vendor, versatility, Wall
Removed:
agent, APB, attached, attestation, authority, automatically, call, cleanser, close, collectibility, comparative, converted, convertible, customary, denominator, EITF, exhibit, expanding, forma, forward, greatly, hospitalization, Intercompany, introduced, involvement, lavage, line, memo, modified, molecule, nasal, numerator, occurring, permit, placement, prepaid, pro, promissory, recently, repayment, reservoir, retail, reverse, safer, separately, shareholder, short, show, speed, split, stabilize, superseded, therapy, trademarked, usable, vested, wholesaler, wholly
Filing tables
Filing exhibits
- 10-K Annual report
- 10.24 Amendment No. 2 to the Collaboration and License Agreement, Dated As of December 2, 2010, Between the Company and Galderma S.a.
- 10.25 Amendment No. 1 to the Collaboration and License Agreement Dated November 18, 2010 by and Between the Company and Alcon Manufacturing, LTD.
- 23.1 Consent of Odenberg, Ullakko, Muranishi & Co. LLP
- 23.2 Consent of Davidson & Co, LLP
- 31.1 Certification of the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-oxley Act of 2002
- 31.2 Certification of the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-oxley Act of 2002
- 23.1 Certification of the Chief Executive Officer Pursuant to Section 906 of the Sarbanes-oxley Act of 2002
- 23.2 Certification of the Chief Financial Officer Pursuant to Section 906 of the Sarbanes-oxley Act of 2002
NBY similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. §1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the annual report of NovaBay Pharmaceuticals, Inc. (the Company) on Form 10-K for the fiscal year ended December 31, 2010 (the Report), I, Ramin (Ron) Najafi, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge:
1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: March 8, 2011
/s/ Ramin Najafi |
Ramin (Ron) Najafi
Chairman and Chief Executive Officer
This Certification is made solely for the purpose of 18 USC Section 1350, subject to the knowledge standard contained therein, and not for any other purpose.